Current Concepts of Cardiac Amyloidosis: Diagnosis, Clinical Management, and the Need for Collaboration

Heart Failure Clinics

Volumn 13, Issue 2, 2017, Pages 409-416

  Ritts, Alexandra J ^a   Cornell, Robert F ^a   Swiger, Kris ^a   Singh, Jai ^a   Goodman, Stacey ^a   Lenihan, Daniel J ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiac amyloidosis; Cardiotoxicity; Immunomodulatory drugs; Multiple myeloma; Proteasome inhibitors; TTR

Indexed keywords

AMYLOID; BIOLOGICAL MARKER; PREALBUMIN; PYROPHOSPHATE TECHNETIUM TC 99M;

CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; GENETIC SCREENING; HEART AMYLOIDOSIS; HEART MUSCLE BIOPSY; HUMAN; NON INVASIVE PROCEDURE; REVIEW; STEM CELL TRANSPLANTATION; SYMPTOMATOLOGY; AMYLOIDOSIS; DISEASE MANAGEMENT; EARLY DIAGNOSIS; GENETICS; HEART DISEASES; METABOLISM;

AMYLOIDOSIS; DISEASE MANAGEMENT; EARLY DIAGNOSIS; HEART DISEASES; HUMANS;

EID: 85014424348     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2016.12.003     Document Type: Review

References (38)

1. 1 Merlini, G., Bellotti, V., Molecular mechanisms of amyloidosis. N Engl J Med 349 (2003), 583–596.
2. 2 Wechalekar, A.D., Gillmore, J.D., Hawkins, P.N., Systemic amyloidosis. Lancet 387 (2016), 2641–2654.
3. 3 Gertz, M.A., Dispenzieri, A., Sher, T., Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol 12 (2015), 91–102.
4. 4 Gertz, M.A., Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol 91 (2016), 947–956.
5. 5 Falk, R.H., Alexander, K.M., Liao, R., et al. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol 68 (2016), 1323–1341.
6. 6 Maurer, M.S., Hanna, M., Grogan, M., et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 68 (2016), 161–172.
7. 7 Zhen, D.B., Swiecicki, P.L., Zeldenrust, S.R., et al. Frequencies and geographic distributions of genetic mutations in transthyretin- and non-transthyretin-related familial amyloidosis. Clin Genet 88 (2015), 396–400.
8. 8 Plante-Bordeneuve, V., Said, G., Familial amyloid polyneuropathy. Lancet Neurol 10 (2011), 1086–1097.
9. 9 Ruberg, F.L., Maurer, M.S., Judge, D.P., et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J 164 (2012), 222–228.e1.
10. 10 Ruberg, F.L., Berk, J.L., Transthyretin (TTR) cardiac amyloidosis. Circulation 126 (2012), 1286–1300.
11. 11 Falk, R.H., Quarta, C.C., Dorbala, S., How to image cardiac amyloidosis. Circ Cardiovasc Imaging 7 (2014), 552–562.
12. 12 Quarta, C.C., Solomon, S.D., Uraizee, I., et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation 129 (2014), 1840–1849.
13. 13 Dorbala, S., Vangala, D., Bruyere, J. Jr., et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail 2 (2014), 358–367.
14. 14 Falk, R.H., Cardiac amyloidosis: a treatable disease, often overlooked. Circulation 124 (2011), 1079–1085.
15. 15 Gonzalez-Lopez, E., Gallego-Delgado, M., Guzzo-Merello, G., et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36 (2015), 2585–2594.
16. 16 Mohammed, S.F., Mirzoyev, S.A., Edwards, W.D., et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2 (2014), 113–122.
17. 17 Kumar, S., Dispenzieri, A., Lacy, M.Q., et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30 (2012), 989–995.
18. 18 Damy, T., Maurer, M.S., Rapezzi, C., et al. Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart, 3, 2016, e000289.
19. 19 Swiger, K.J., Friedman, E.A., Brittain, E.L., et al. Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis. Amyloid 23 (2016), 1–7.
20. 20 Senapati, A., Sperry, B.W., Grodin, J.L., et al. Prognostic implication of relative regional strain ratio in cardiac amyloidosis. Heart 102 (2016), 748–754.
21. 21 Boynton, S.J., Geske, J.B., Dispenzieri, A., et al. LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis. JACC Cardiovasc Imaging 9 (2016), 680–686.
22. 22 Gillmore, J.D., Maurer, M.S., Falk, R.H., et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133 (2016), 2404–2412.
23. 23 Castano, A., Haq, M., Narotsky, D.L., et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol 1 (2016), 880–889.
24. 24 Kristen, A.V., Brokbals, E., Aus dem Siepen, F., et al. Cardiac amyloid load: a prognostic and predictive biomarker in patients with light-chain amyloidosis. J Am Coll Cardiol 68 (2016), 13–24.
25. 25 Swiecicki, P.L., Zhen, D.B., Mauermann, M.L., et al. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid 22 (2015), 123–131.
26. 26 Dispenzieri, A., Gertz, M.A., Kyle, R.A., et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22 (2004), 3751–3757.
27. 27 Palladini, G., Hegenbart, U., Milani, P., et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 124 (2014), 2325–2332.
28. 28 Grogan, M., Scott, C.G., Kyle, R.A., et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68 (2016), 1014–1020.
29. 29 Selvanayagam, J.B., Hawkins, P.N., Paul, B., et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 50 (2007), 2101–2110.
30. 30 Tan, N.Y., Mohsin, Y., Hodge, D.O., et al. Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol 27 (2016), 1167–1173.
31. 31 Sperry, B.W., Ikram, A., Hachamovitch, R., et al. Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J Am Coll Cardiol 67 (2016), 2941–2948.
32. 32 Sher, T., Dispenzieri, A., Gertz, M.A., Evolution of hematopoietic cell transplantation for immunoglobulin light chain amyloidosis. Biol Blood Marrow Transpl 22 (2016), 796–801.
33. 33 Warsame, R., Bang, S.M., Kumar, S.K., et al. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. Eur J Haematol 92 (2014), 485–490.
34. 34 D'Souza, A., Dispenzieri, A., Wirk, B., et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a center for International Blood and Marrow Transplant Research Study. J Clin Oncol 33 (2015), 3741–3749.
35. 35 Gertz, M.A., Benson, M.D., Dyck, P.J., et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 66 (2015), 2451–2466.
36. 36 Brunjes, D.L., Castano, A., Clemons, A., et al. Transthyretin cardiac amyloidosis in older Americans. J Card Fail 22:12 (2016), 996–1003.
37. 37 Berk, J.L., Suhr, O.B., Obici, L., et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310 (2013), 2658–2667.
38. 38 Davis, M.K., Kale, P., Liedtke, M., et al. Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. Am J Transplant 15 (2015), 650–658.